Title of article :
Serum and Urine Levels of Vascular Endothelial Growth Factor as Prognostic Markers in Patients with Bladder Cancer
Author/Authors :
Ayati, Mohsen Uro-Oncology Research Center - Tehran University of Medical Sciences, Tehran, Iran , Amini, Erfan Uro-Oncology Research Center - Tehran University of Medical Sciences, Tehran, Iran , Ghorani, Hossein Uro-Oncology Research Center - Tehran University of Medical Sciences, Tehran, Iran , Nowroozi, Mohammad Reza Uro-Oncology Research Center - Tehran University of Medical Sciences, Tehran, Iran , Jamshidian, Hassan Uro-Oncology Research Center - Tehran University of Medical Sciences, Tehran, Iran , Ohadian Moghadam, Solmaz Uro-Oncology Research Center - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
Background: Bladder cancer is the second most common urinary cancer after
prostate cancer. Recent studies have shown higher serum and urinary vascular
endothelial growth factor (VEGF) in increased angiogenesis. In this study, the mean
serum and urine level of VEGF was assessed in patients with bladder cancer.
Methods: In this case-control study, 46 patients with bladder cancer referred to
Imam-Khomeini Hospital in Tehran, Iran and 38 subjects as control, were enrolled
and the mean serum and urine level of VEGF was assessed and compared between
the groups.
Results: The mean serum level of VEGF was 478.7, 518.4, and 648.1 in control,
low-grade, and high-grade groups, respectively, with no significant difference (P=0.175).
The mean urine level of VEGF was 414.2, 968.3, and 848.4 in control, low-grade,
and high-grade groups, respectively, with significant difference (P=0.010).
Conclusion: The mean urine level of VEGF in patients with bladder cancer is
higher than healthy subjects
Keywords :
Vascular endothelial growth factor (VEGF) , Bladder cancer , Tumor marker
Journal title :
Middle East Journal of Cancer (MEJC)
